ClinicalTrials.gov
ClinicalTrials.gov Menu

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01088620
Recruitment Status : Suspended (the DSMB stopped the trial due to unacceptable side effects in the experimental arm which has not yet been verified)
First Posted : March 17, 2010
Last Update Posted : March 14, 2013
Sponsor:
Collaborator:
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Information provided by (Responsible Party):
WiSP Wissenschaftlicher Service Pharma GmbH